Sirt1 improves heart failure through modulating the NF-κB p65/microRNA-155/BNDF signaling cascade

Bin Lin¹, Hui Zhao¹, Li Li¹, Zhenzheng Zhang¹, Nan Jiang¹, Xiaowei Yang¹, Tao Zhang¹, Bowen Lian¹, Yaokai Liu¹, Chi Zhang¹, Jiaxiang Wang¹, Feng Wang¹, Deguang Feng¹,², Jing Xu¹

¹Department of Cardiovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China

Correspondence to: Deguang Feng; email: drfengdeguang@163.com, https://orcid.org/0000-0003-2875-5563
Keywords: heart failure, Sirt1, NF-κB p65, microRNA-155, BDNF
Received: February 12, 2020   Accepted: June 18, 2020   Published: November 18, 2020

ABSTRACT

Heart failure (HF) affects over 26 million people worldwide, yet the pathologies of this complex syndrome have not been completely understood. Here, we investigated the involvement of deacetylase Sirtuin 1 (Sirt1) in HF and its downstream signaling pathways. A HF model was induced by the ligation of the left coronary artery in rats, where factors associated with left ventricular echocardiography, heart hemodynamics and ventricular mass indexes were recorded. Collagen volume fraction in heart tissues was determined by Masson’s trichrome staining. Cell models of HF were also established (H2O2, 30 min) in cardiomyocytes harvested from suckling rats. HF rats presented with downregulated expressions of Sirt1, brain-derived neurotrophic factor (BDNF) and exhibited upregulated expressions of NF-κB p65 and miR-155. Repressed Sirt1 expression increased acetylation of NF-κB p65, resulting in the elevation of NF-κB p65 expression. NF-κB p65 silencing improved heart functions, decreased ventricular mass and reduced apoptosis in cardiomyocytes. MiR-155 inhibition upregulated its target gene BDNF, thereby reducing cardiomyocyte apoptosis. Sirt1 overexpression upregulated BDNF, improved heart function, and reduced apoptosis in cardiomyocytes. In conclusion, Sirt1 alleviates HF in rats through the NF-κB p65/miR-155/BDNF signaling cascade.

INTRODUCTION

Heart failure (HF) is a global health burden, affecting more than 26 million people [1]. It is a complex clinical syndrome that may be caused by functional and/or structural impairment of the heart [2]. Although HF can be caused by different etiologies, there is a growing patient population that have HF, with left ventricular impairment and ejection deficiency, which currently does not have any specific treatment guidelines [3]. Half of the HF patients were hypertensive in China; however, approximately 30% were using anti-hypertensive medications [4]. The average duration of hospitalization of HF patients in China was 9-10 days, thereby exerting a huge economic burden on society [5]. Cardiomyocyte apoptosis has been reported as one of the causes for adverse remodeling, thus contributing to HF at later phase [6]. It is, therefore, of great importance to inhibit cardiomyocyte apoptosis to improve the treatment and outcomes of HF.

Ineffective treatment for HF is partially attributed to complex pathologies that have not been fully understood. Sirtuin (Sirt) is a family of highly conserved histone/protein deacetylases that may be important for the treatment of HF [7]. Among Sirt family, Sirt1 and Sirt3 have been extensively studied in the cardiovascular system. Sirt1 is particularly noteworthy because of its effect on cardiomyocyte survival and growth under stress, which is associated with ventricular hypertrophy [8]. Moreover, Sirt1 protects cardiomyocytes against oxidative stress, ischemia/reperfusion injury, and apoptosis [9]. Sirt1 has an inhibitory effect on nuclear factor kappa-light-chain-enhancer of activated B cells.
NF-κB p65 is highly expressed in HF and promotes microRNA-155 (miR-155) expression [16-18], which promotes HF [19]. MiR-155 is recently found to be a regulator of brain-derived neurotrophic factor (BDNF), with the expression of BNF being reduced in HF [20-23]. These previous findings led us to further determine the downstream molecular mechanism of NF-κB p65-mediated injury in cardiomyocytes that involves miR-155 and BDNF in HF.

RESULTS

Characterization of HF rat models

We initially established an animal rat model with HF after myocardial infarction according to the method of left coronary artery ligation. Ultrasonic echocardiogram test results suggested that HF rats had higher interventricular septal dimension (IVSD), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD). In contrast, HF rats had decreased left ventricular posterior wall thickness (LVPWD), left ventricular ejection fraction (LVEF), and fractional shortening (FS) compared to that of control or sham rats (Table 1). The LVEF in HF rats were less than or equal to 45%. There were no differences in LVEF between the control and sham rats. Hemodynamic measurements revealed that left ventricular end diastolic pressure (LVEDP) was significantly elevated, while left ventricular systolic pressure (LVSP), left ventricular pressure (+dp/dt) and the rate of decrease in left ventricular pressure (-dp/dt) were significantly decreased in HF rats compared to that of control and sham rats (Table 2). Both left ventricular mass index (LVMI) and right ventricular mass index (RVMI) were significantly higher in HF rats than those of control and sham rats (Figure 1A).

Sirt1 is poorly expressed while NF-κB p65 is highly expressed in heart tissues rats with HF

Messenger RNA (Figure 1B) and protein (Figure 1C) expressions of Sirt1 were determined using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. The results displayed significantly reduced mRNA and protein Sirt1 expressions in heart tissues of HF rats in contrast with that of control or sham rats. On the other hand, protein expression of NF-κB p65 and NF-κB p65 Ac was significantly increased in HF rats when compared to control and sham rats (Figure 1C). Collagen volume fraction (CVF) (Figure 1D) and cardiomyocytes apoptosis (Figure 1E) were increased in HF rats compared to that of control or sham rats. The above results indicated that Sirt1 expression was elevated, NF-κB p65 in heart tissues of HF rats was upregulated, while acetylation of NF-κB p65 was inhibited in HF rats.

NF-κB p65 silencing alleviates HF

Since NF-κB p65 expression was increased in HF rats, we hypothesized that the silencing of NF-κB p65 would improve the outcome of HF in rats. In order to test this hypothesis, we silenced NF-κB p65 expression. Among 3 sh-RNA, sh-NF-κB p65#2 reduced NF-κB p65 most significantly and therefore was chosen for subsequent experiments (Figure 2A). sh-NF-κB p65 also reduced the protein expression of NF-κB p65 when compared to its NC (Figure 2B). NF-κB p65 silencing reduced LVSD, LVEDD and LVESD, while increasing LVPWD, LVEF, and FS in HF rats (Table 3). NF-κB p65 silencing also reduced LVEDP and increased LVSP, +dp/dt, and -dp/dt in hemodynamic measurements. However, the heart rate (HR) of rats among different groups did not vary noticeably (Table 4). NF-κB p65 silencing also reduced LVMI and RVMI (Figure 2C), CVF (Figure 2D), and cardiomyocytes apoptosis (Figure 2E) in HF rats. Collectively, NF-κB p65 silencing alleviated HF.

NF-κB p65 binds to the promoter region and elevates miR-155 expression in cardiomyocytes

The expression of miR-155 was significantly higher in HF rats and was partially reduced after NF-κB p65 silencing (Figure 3A). MiR-155 expression remained unchanged in the control and sham rats. The enrichment of NF-κB p65 in the miR-155 promoter region was significantly higher in HF rat cardiomyocytes, which was subsequently reduced by NF-κB p65 silencing (Figure 3B). Furthermore, NF-κB p65 overexpression increased miR-155 expression, whereas NF-κB p65 silencing reduced miR-155 expression (Figure 3C). These results showed that NF-κB p65 upregulated miR-155 by binding to the promoter region of miR-155.

MiR-155 inhibition reduces cardiomyocyte apoptosis in cell models of HF

MiR-155 expression was increased in cardiomyocytes treated with H2O2 and reduced by a miR-155 inhibitor
Table 1. Echocardiographic data in all groups of rats.

| Group | LVPWD (mm)   | IVSD (mm)   | LVEDD (mm) | LVESD (mm) | LVEF (%)  | FS (%)   |
|-------|--------------|-------------|------------|------------|-----------|----------|
| Control | 1.58 ± 0.17 | 1.44 ± 0.15 | 4.01 ± 0.42 | 2.08 ± 0.24 | 71.14 ± 8.07 | 25.16 ± 3.34 |
| Sham   | 1.67 ± 0.17 | 1.51 ± 0.21 | 4.17 ± 0.43 | 2.26 ± 0.31 | 73.41 ± 7.56 | 27.15 ± 3.64 |
| HF     | 0.79 ± 0.08*| 2.84 ± 0.35*| 7.46 ± 0.84*| 4.29 ± 0.51*| 34.16 ± 3.62*| 16.34 ± 2.04*|

Note: *p < 0.05 vs. control and sham rats. HF, heart failure; LVPWD, left ventricular posterior wall thickness; IVSD, interventricular septal dimension; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; FS, fractional shortening.

Table 2. Cardiac hemodynamic parameters in all groups of rats.

| Group | LVSP (mm Hg) | LVEDP (mm Hg) | HR (bpm) | +dp/dt (mm Hg/s) | -dp/dt (mm Hg/s) |
|-------|--------------|---------------|----------|------------------|------------------|
| Control | 115.41±15.16 | 6.16±0.63     | 294.45±30.01 | 4497.45±340.56   | 2768.57±312.08   |
| Sham   | 112.15±10.24 | 7.75±0.82     | 276.81±35.07 | 4167.61±486.43   | 2506.34±401.07   |
| HF     | 57.16±6.01*  | 24.67±2.64*   | 265.16±26.79 | 1976.37±204.16*  | 1046.31±186.19*  |

Note: *p < 0.05 vs. control rats. # p < 0.05 vs. sham rats. LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; HR, heart rate; +dp/dt, rate of increase in left ventricular pressure; -dp/dt, rate of decrease in left ventricular pressure.

(Figure 4A). Cell viability in HF cells was significantly lower than that of the control cells (left panel, Figure 4B). The miR-155 inhibitor significantly increased cell viability in HF cells (right panel, Figure 4B). H$_2$O$_2$ treatment also increased apoptosis and was normalized by an miR-155 inhibitor (Figure 4C). Similarly, H$_2$O$_2$ treatment increased apoptosis-related proteins Bax and cleaved-caspase3 prominently while at the same time decreased anti-apoptosis-related Bcl-2 protein (Figure 4D). The miR-155 inhibitor reversed the aforementioned effects mentioned above. These results suggested that miR-155 reduced cardiomyocyte apoptosis in HF.

**MiR-155 downregulates BDNF and promotes cardiomyocyte apoptosis**

Online database mirDIP, RNA22, miRWalk, and starBase searches predicted that BDNF has a binding
site for miR-155 (Figure 5A). We further studied this binding relationship by using a dual luciferase reporter gene assay. Luciferase activity in the BDNF-wild-type (WT)/miR-155 mimic group was significantly lower than that of mimic NC group (Figure 5B). However, there were no differences in luciferase activity between the BDNF-mutated (MUT)/miR-155 mimic group and mimic NC group. This indicates that miR-155 specifically binds to the BDNF (Figure 5B). BDNF mRNA (Figure 5C) and protein (Figure 5D) expressions in the heart of HF rats were significantly lower than that in control and sham rats. These results suggested that BDNF may be related to HF involving miR-155.

In cardiomyocytes treated with H₂O₂, the miR-155 inhibitor significantly reduced the mRNA (Figure 5E) and protein (Figure 5F) expressions of miR-155 but on the other hand, increased BDNF levels. Conversely, miR-155 mimic increased miR-155 expression but reduced BDNF. MiR-155 mimic decreased cell viability (Figure 5G) and increased apoptosis (Figure 5H) in HF cardiomyocytes. BDNF overexpression normalized the effect of miR-155 mimic. Similarly, miR-155 mimic was found to upregulate Bax and cleaved-caspase3 while decreasing Bcl-2, but this trend was prevented by BDNF overexpression (Figure 5I). These results indicated miR-155 overexpression inhibited BDNF expression and promoted cardiomyocyte apoptosis. Therefore, miR-155 inhibition up-regulated BDNF and reduced cardiomyocytes apoptosis and thus may be beneficial to HF.

**MiR-155/BDNF axis attenuates HF in vivo**

MiR-155 antagonir significantly decreased mRNA (Figure 6A) and protein (Figure 6B) expressions of miR-155 while increasing that of BDNF in heart tissues of HF rats. The addition of sh-BDNF exhibited no effect on the expression of miR-155, but decreased that of BDNF in miR-155 antagonir-treated HF rats. MiR-155 antagonir decreased IVSD, LVEDD, and LVESD while increasing LVPWD, LVEF, and FS in HF rats (Table 5). BDNF silencing significantly increased IVSD, LVEDD, and LVESD and decreased LVPWD, LVEF, and FS in miR-155 antagonir-treated HF rats. MiR-155 antagonir decreased LVEDP while increasing LVSP, +dp/dt, and -dp/dt (Table 6). As expected, BDNF silencing significantly increased LVEDP and decreased LVSP, +dp/dt, and -dp/dt in miR-155 antagonir-treated HF rats. There was no noteworthy difference in HR between groups. LVMI, RVMI (Figure 6C), CVF (Figure 6D), and cardiomyocytes apoptosis (Figure 6E) were significantly lowered by miR-155 antagonir and were normalized by BDNF silencing in heart tissues of HF rats. These results indicated that miR-155 inhibition upregulated BDNF expression and alleviated HF in vivo.

**Sirt1 overexpression alleviates HF in vivo**

Sirt1 overexpression reduced NF-κB p65 and NF-κB p65 Ac protein expressions in heart tissues of HF rats (Figure 7A). Sirt1 overexpression led to increased

---

Figure 2. Effects of NF-κB p65 silencing on heart failure in rats. (A) NF-κB p65 mRNA expression after sh-RNA treatment; (B) NF-κB p65 protein expression in heart tissues; (C) Ventricular mass index; (D) CVF determined by Masson’s trichrome staining (100 ×); (E) Apoptosis determined by TUNEL staining (200 ×); *p < 0.05 vs. model + sh-NC group; # indicates lowest NF-κB p65 mRNA expression. Data are expressed as mean ± standard deviation. A comparison of data from 2 groups was performed by an unpaired t test, while 3 or more groups were performed by one-way analysis of variance (ANOVA) and Tukey’s post hoc test. N= 12.
Table 3. Effects of NF-κB p65 silencing on heart functions.

| Group                  | LVPWD (mm) | IVSD (mm) | LVEDD (mm) | LVESD (mm) | LVEF (%) | FS (%) |
|------------------------|------------|-----------|------------|------------|----------|--------|
| Model + sh-NC          | 1.07±0.12  | 2.64±0.31 | 6.17±0.72  | 4.12±0.43  | 32.76±4.54 | 15.23±1.74 |
| Model + sh-NF-κB p65   | 1.36±0.19* | 1.24±0.16*| 2.91±0.39* | 1.54±0.21* | 67.34±7.84* | 23.16±2.69* |

Note: *p < 0.05 vs. model + sh-NC group. NC, negative control; miR-155, microRNA-155; BNDF, brain-derived neurotrophic factor; LVPWD, left ventricular posterior wall thickness; IVSD, interventricular septal dimension; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; FS, fractional shortening.

Table 4. Effects of NF-κB p65 silencing on hemodynamics of the heart.

| Group                  | LVSP (mm Hg) | LVEDP (mm Hg) | HR (bpm) | +dp/dt (mm Hg/s) | -dp/dt (mm Hg/s) |
|------------------------|--------------|---------------|----------|------------------|------------------|
| Model + sh-NC          | 48.26 ± 4.91 | 20.13 ± 2.46  | 276.15 ± 31.24 | 1724.71 ± 186.72 | 996.14 ± 100.26 |
| Model + sh-κB p65      | 104.37±11.28* | 5.01±0.72*    | 281.47±33.24 | 4067.38±412.34* | 1817.21±204.37* |

Note: *p < 0.05 vs. model + sh-NC group. NC, negative control; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; HR, heart rate; +dp/dt, rate of increase in left ventricular pressure; -dp/dt, rate of decrease in left ventricular pressure.

BDNF expression. Moreover, Sirt1 overexpression reduced miR-155 expression (Figure 7B). These results indicated that the overexpression of Sirt1 downregulated NF-κB p65 by inhibiting NF-κB p65 acetylation, thus leading to reduced miR-155 expression and an increased BDNF expression.

Sirt1 overexpression reduced IVSD, LVEDD, and LVESD while elevated LVPWD, LVEF, and FS in HF rats (Table 7). Heart hemodynamic studies showed that LVEDP was significantly decreased, while LVSP, +dp/dt, and -dp/dt were increased by Sirt1 overexpression (Table 8). The HR was not different among the different groups. LVMI, RVMI (Figure 7C), CVF (Figure 7D), and cardiomyocytes apoptosis (Figure 7E) were reduced in HF rats by the overexpression of Sirt1. These results indicated that the overexpression of Sirt1 exhibited protective effects against HF.

DISCUSSION

HF is a complex disease that has a wide variety of etiological causes and mechanisms of action, many of which are still not properly understood. There are multiple animal and cell models to mimic certain, but not all, aspects of HF [24, 25]. In this study, we used an artery ligation rat model to mimic ischemic injury and an H2O2-induced cardiomyocyte injury cell model.

Figure 3. Binding relationship between NF-κB p65 and miR-155. (A) miR-155 expression in heart tissues; (B) Enrichment of NF-κB p65 in the promoter region of miR-155 determined by ChIP assay; (C) miR-155 expression in cardiomyocytes; *p < 0.05 vs. control, oe-NC or sh-NC group; #p < 0.05 vs. sham group; ^p < 0.05 vs. model + sh-NC group. Data were expressed as a mean ± standard deviation. Three or more groups by one-way analysis of variance (ANOVA) and Tukey’s post hoc test. N= 12.
Collectively, reduced Sirt1 expression in HF lead to increased NF-κB p65 and miR-155 expressions, reduced BDNF expression, which promoted HF.

Sirt1 expression is shown to be reduced in HF [13]. The reduced expression of Sirt1 in HF is consistent to the increased acetylation in HF [26, 27]. Similarly, we found that a reduction in Sirt1 expression produced an increase in levels of acetylation and expression of NF-κB p65. Therefore, we expected that increased Sirt1 expressions would prevent injuries in cardiomyocytes and hence avoid the subsequent progression to HF. We also discovered that Sirt1 overexpression increased cell viability, reduced apoptosis, and improved heart function in HF rats. These results agree with previous studies by showing the beneficial effects of Sirt1 on HF including: improving cell survival, reducing oxidative stress, and reducing ischemia/reperfusion injury [8, 9, 28, 29]. Therefore, Sirt1 may be a novel target for the treatment of HF [7, 30].

The increased levels of protein acetylation are well-known in HF. It is postulated that acetylation is caused by ischemic stress, leading to metabolic dysfunction especially in mitochondria [26]. The acetylation of metabolic-relevant, non-histone-related proteins such as ATP synthase, long-chain acyl-CoA dehydrogenase, creatine kinase, malate dehydrogenase, and pyruvate dehydrogenase can be visibly seen in the mitochondria of failing hearts [31]. Acetylation of histone-related

---

**Figure 4. Effects of miR-155 inhibition on cardiomyocyte apoptosis.** (A) Expression of miR-155; (B) Cell viability determined by MTT assay; (C) Cell apoptosis determined by flow cytometry; (D) Protein expression of apoptosis-related factors; *p < 0.05 vs. control group or model + inhibitor NC. Data were expressed as a mean ± standard deviation. Three or more groups were analyzed by one-way analysis of variance (ANOVA) and Tukey’s post hoc test. Data comparison between different time points was performed by repeated measures ANOVA and Bonferroni post hoc test. The cell experiment was repeated three times.
Figure 5. Effects of miR-155 and BDNF on cardiomyocyte apoptosis. (A) Binding relationship between miR-155 and BDNF predicted by online tools; (B) Binding relationship between miR-155 and BDNF determined by dual luciferase reporter gene assay; (C) BDNF mRNA
expression in heart tissues; (D) BDNF protein expression in heart tissues; (E) miR-155 and BDNF mRNA expression in cardiomyocytes. (F) BDNF protein expression in cardiomyocytes; (G) Cell viability determined by MTT assay; (H) Cell apoptosis determined by flow cytometry; (I) Protein expression of apoptosis-related factors; *p < 0.05 vs. control, model + inhibitor NC, model + mimic NC, or model + miR-155 mimic + oe-NC groups; #p < 0.05 vs. sham group. Data were expressed as a mean ± standard deviation. A comparison of data from 2 groups was performed by an unpaired t test, while 3 or more groups by one-way analysis of variance (ANOVA) and Tukey’s post hoc test. Data comparison between different time points was performed by repeated measures ANOVA and Bonferroni post hoc test. N= 12. The cell experiment was repeated three times.

proteins, on the other hand, has been shown to be responsible for an increased heart mass, such as left ventricular hypertrophy in HF [32]. In this study, we reported to the best of our knowledge, that the acetylation of NF-κB was increased in heart tissues during HF because of reduced deacetylase Sirt1. Our results supported the idea that acetylation is a potential target for treating HF [33, 34].

Figure 6. Effects of miR-155 and BDNF on heart failure in vivo. (A) Expression of miR-155 and BDNF mRNA expression; (B) BDNF protein expression; (C) Ventricular mass index; (D) CVF determined by Masson’s trichrome staining (100 ×); (E) Apoptosis determined by TUNEL staining (200 ×); *p < 0.05 vs. model + NC antagonist or model + miR-155 antagonist + sh-NC group. Data were expressed as mean ± standard deviation. A comparison of data from 2 groups were performed by unpaired t test. N= 12.
Table 5. Effects of miR-155 and BDNF inhibition on heart functions in HF rats.

| Group                               | LVPWD (mm) | IVSD (mm) | LVEDD (mm) | LVESD (mm) | LVEF (%) | FS (%) |
|-------------------------------------|------------|-----------|------------|------------|----------|--------|
| Model + NC antagomir                | 0.84±0.09  | 1.37±0.34 | 3.96±0.54  | 1.92±0.39  | 33.17±1.37 | 11.64±1.27 |
| Model + miR-155 antagomir           | 1.23±0.16* | 0.78±0.17*| 1.25±0.34* | 1.01±0.21* | 68.16±2.76* | 23.38±2.14* |
| Model + miR-155 antagomir + sh-NC   | 1.34±0.15  | 0.62±0.14 | 1.42±0.28  | 1.16±0.23  | 69.14±2.72 | 23.08±2.31 |
| Model + miR-155 antagomir + sh-BDNF| 0.76±0.08* | 1.41±0.29*| 3.73±0.79* | 2.07±0.32* | 31.05±1.34* | 11.25±0.96* |

Note: *p < 0.05 vs. model + NC antagomir or model + miR-155 antagomir + sh-NC group. HF, heart failure; NC, negative control; miR-155, microRNA-155; BDNF, brain-derived neurotrophic factor; LVPWD, left ventricular posterior wall thickness; IVSD, interventricular septal dimension; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; FS, fractional shortening.

Table 6. Effects of miR-155 and BDNF inhibition on heart hemodynamics in HF rats.

| Group                               | LVSP (mm Hg) | LVEDP (mm Hg) | HR (bpm) | +dp/dt (mm Hg/s) | -dp/dt (mm Hg/s) |
|-------------------------------------|--------------|---------------|----------|------------------|------------------|
| Model + NC antagomir                | 53.64±5.86   | 22.46±2.47    | 249.21±26.85 | 1921.26±203.16  | 1017.24±129.24  |
| Model + miR-155 antagomir           | 93.34±9.46*  | 5.34±0.71*    | 261.37±25.89 | 4054.23±463.79* | 2364.69±217.45* |
| Model + miR-155 antagomir + sh-NC   | 109.56±15.24 | 4.21±0.63     | 279.34±31.26 | 4212.34±465.79  | 2169.37±301.75  |
| Model + miR-155 antagomir + sh-BDNF| 49.67±5.79*  | 21.04±2.76*   | 278.76±34.19 | 1863.27±197.64* | 996.17±107.65*  |

Note: *p < 0.05 vs. model + NC antagomir or model + miR-155 antagomir + sh-NC group. HF, heart failure; NC, negative control; miR-155, microRNA-155; BDNF, brain-derived neurotrophic factor; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; HR, heart rate; +dp/dt, rate of increase in left ventricular pressure; -dp/dt, rate of decrease in left ventricular pressure.

Figure 7. Effects of Sirt1 overexpression on heart failure in vivo. (A) Sirt1, NF-κB p65, NF-κB p65 Ac and BDNF protein expression; (B) miR-155 expression; (C) Ventricular mass index; (D) CVF determined by Masson’s trichrome staining (100 ×); (E) Apoptosis determined by TUNEL assay (200 ×); *p < 0.05 vs. model + oe-NC group. Data were expressed as mean ± standard deviation. A comparison of data from 2 groups was performed by an unpaired t test. N= 12.
In the subsequent experiments, we found that a reduced Sirt1 expression led to an increased level of NF-κB. This result was in line with previous findings that Sirt1 exerts an inhibitory effect on NF-κB [10, 11]. NF-κB is a transcription factor that involves many biological and pathological functions. It is speculated that NF-κB may cause overactive immune and/or inflammatory responses that promotes injury in HF [35]. On the other hand, NF-κB may promote HF by directly initiating cell death in cardiomyocytes [36]. The effects of NF-κB on HF may involve its target gene, miR-155, which is shown in previous studies [16, 17]. MiR-155 may be involved in HF based on a few observations. Our results showed that miR-155 inhibition decreased ventricular hypertrophy, cardiomyocyte apoptosis and increased cardiac functions. Moreover, a previous study demonstrated that miR-155 is highly expressed in HF and has been proposed to promote ventricular hypertrophy and dysfunction [17, 19]. Our results also presented that miR-155 overexpression increased cardiomyocyte apoptosis and expression of BDNF. Consistently, the inhibition of miR-155 suppresses the cardiomyocyte apoptosis induced by myocardial ischemia/reperfusion [37] or endoplasmic reticulum stress [38].

MiR-155 has been recently found to regulate BDNF [20, 21]. Similarly in our study, we found that miR-155 mimic reduced BDNF expression. Although the majority of the research on BDNF has been conducted on the brain, one report elucidates the role of BDNF in the neuronal-cardiac link [39]. For example, BDNF may have a role in the neuronal control of contraction and relaxation in cardiomyocytes, therefore having a physiological role in regulating heartbeat [40]. BDNF may also be protective against ischemia/reperfusion-induced cell deaths in the heart [41]. Our results were similar in a way that BDNF silencing prevented many beneficial effects of miR-155 inhibition including: reduced cardiomyocytes apoptosis, ventricular hypertrophy, and improved heart function in vivo. These results collectively provide strong evidence that reduced BDNF may have a role in causing ventricular dysfunction in HF. In other words, increased BDNF expression in cardiomyocytes may be beneficial to heart function in HF.

CONCLUSIONS

In conclusion, this study suggests that increased NF-κB expression in cardiomyocytes, induced by the attenuated expression of Sirt1, upregulates miR-155. An increased expression of miR-155 in cardiomyocytes inhibits the expression of BDNF, leading to ventricular dysfunction in HF. All signaling molecules in this pathway warrant further investigation as potential pharmaceutical targets against injuries in cardiomyocytes during HF. Additionally, other models should also be explored and help confirm results from this study because these two models only mimic part of the human disease.

MATERIALS AND METHODS

All animal procedures were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health and approved by the Animal Ethics Committee of The First Affiliated Hospital of Zhengzhou University.
Establishment of a rat model of HF

Healthy male Sprague-Dawley rats (207 ± 20 g, n = 120, Animal Experimental Center, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China) were kept in a pathogen-free animal facility at (22 ± 3)°C, with a relative humidity 40-70%, in a 12 hour/12 hour light/dark cycle with free access to food and water. Rats were randomly divided into control (n = 12), sham (n = 12), and HF groups (n = 96). HF in rats was induced by the ligation of the left coronary artery between the left atrial appendage and the pulmonary artery, as described previously [42]. Sham rats received coronary artery exposure and suture threaded without ligation. Four weeks after the surgery, echocardiographic determination (SonoAce X8, Jumu Medical Devices Co., Ltd., Shanghai, China) of LVEF ≤ 45% was used to make sure that HF was induced successfully [43, 44]. Animals with unsuccessful induction of HF were replaced.

Transfection in HF rats

HF rats were subdivided into 8 groups (n = 12 per group): (1) model + sh-negative control (NC) (NK-κB p65 silencing negative sequence); (2) model + sh-NF-κB p65 (NF-κB p65 silencing plasmid); (3) model + NC antagonimir (miR-155 antagonimir negative sequence); (4) model + miR-155 antagonimir (miR-155 antagonimir oligonucleotide); (5) model + miR-155 antagonimir + sh-NC (miR-155 antagonimir oligonucleotide + BDNF silencing negative sequence); (6) model + miR-155 antagonimir + sh-BDNF (miR-155 antagonimir oligonucleotide + BDNF silencing plasmid); (7) model + oe-Sirt1 overexpression negative sequence); and (8) model + oe-Sirt1 (Sirt1 overexpression plasmid). A transfecting solution (0.5 nM, in 3 μL phosphate buffered saline, PBS) was injected through the tail vein according to instructions provided by the En-transter™-in vivo kit [45]. The control group received 3 μL of PBS [46]. All sequencing and packaging of viral vectors were prepared by GeneChem (Shanghai, China).

Left ventricular echocardiography in HF rats

Rats were anesthetized by pentobarbital sodium (3%, i.p., P3761, Sigma, St. Louis, MO, USA) and secured on a wooden board in the supine position. Hair near the chest area was removed for Doppler ultrasonography (SSI-5000, ShuKang HengTong Science and Trade, Shandong, China) to determine the following: LVPWD, IVSD, LVEDD, LVESD, LVEF and FS.

Heart hemodynamics in HR rats

Rats were anesthetized by pentobarbital sodium and secured on an operating table in the supine position.
by bicinechonic acid kits (20201ES76, Yeasen Biotechnology, Shanghai, China). Lysate volume was diluted to only allow each sample to contain 30 μg protein. Samples were mixed with loading buffer and boiled at 100°C for 5 min. Samples were then cooled with ice, centrifuged, and loaded on sodium dodecyl sulfate polyacrylamide gel electrophoresis separation gel (10%) for electrophoresis. The proteins were transferred onto a nitrocellulose membrane and blocked by 5% skim milk at 4°C overnight. The membranes were incubated with primary rabbit anti-mouse Sirt1 (1: 2000, ab233398), NF-κB p65 (1: 1000, ab28856), NF-κB Ac (1: 500, ab19870), BDNF (1: 2000, ab108319), caspase-3 (1: 500, ab4051), cleaved-caspase3 (1: 500, ab49822), Bax (1: 2000, ab32503), Bcl-2 (1: 1000, ab59348) and GAPDH (1: 2500, ab9485) antibodies for 1 hour at room temperature. The membranes were incubated with horseradish peroxidase labeled secondary goat anti-rabbit IgG (1:5000, ab6721) antibodies for 1 hour at room temperature. The samples were washed by TBST for 5 min each time for a total of 3 times and were incubated with horseradish peroxidase -labeled secondary goat anti-rabbit IgG (1:5000, ab6721) antibodies for 1 hour at room temperature. The samples were washed by TBST for 5 min each time for a total of 3 times. The membranes were developed and images were taken. Gray intensity in protein bands were analyzed by Quantity One software. GAPDH was used as the internal reference. All samples were tested in triplicates and all antibodies were purchased from Abcam, Cambridge, UK.

**Masson’s trichrome staining**

Paraffin-embedded myocardial tissues were dried in an oven at 65°C for 3 hours and dewaxed. Tissues were treated with 10% trichloroacetic acid and 10% potassium dichromate for 40 min each. Tissues were then rinsed with tap water, stained with hematoxylin (PT001, BoGoo Biotechnology Co., Ltd., Shanghai, China) and left alone for 8 min. Tissues were stained with 1% Ponceau S (HL12202, Harling Biotechnology Co., Ltd., Shanghai, China) and 1% Fuchsin (HPBIO-SJ820, Hepeng Biotechnology Co., Ltd., Shanghai, China) for 40 min after being rinsed with tap water. The stain was removed by adding 1% glacial acetic acid, followed by 1% molybdic acid solution. The samples were dehydrated and fixed for observation under a microscope. Basement membrane and collagen fibers were stained blue or green. Immune cells were stained red while nuclei stained blueish brown. Five fields in each sample were randomly selected to be observed under a polarized light microscope. CVF was calculated by Image-Pro plus 5.1 image analysis software (Media Cybernetics, Rockville, MD, USA) based on: CVF (%) = collagen area /full field area × 100%.

**TUNEL staining**

Paraffin-embedded heart sections were dewaxed and soaked in 3% H2O2 methanol solution for 30 min at room temperature. After washing with PBS for 5 min each time for a total of 3 times, proteinase K solution was added to the sections dropwise and incubated at 37°C for 30 min. The sections were incubated in 0.1% Trion X-100 and 0.1% sodium citrate solution for 5 min at room temperature and washed with distilled water each time for a total of 3 times. The sections were incubated with a freshly prepared TUNEL reaction mixture (prepared based on kit manufacturer’s instructions) at 37°C for 90 min. The sections were then washed in TBS for 5 min each time for 3 times at room temperature. Bovine serum albumin blocking solution (5%) was added and incubated for 20 min at room temperature. Bovine serum albumin blocking solution (5%) was added and incubated for 20 min at room temperature in a wet box. POD solution was added and incubated at 37°C for 30 min, followed by washing with TBS for 5 min each time for 2 times. The sections were developed in 3,3′-diaminobenzidine at room temperature under the guidance of a microscope. Color development was stopped by rinsing the sections with water. The cells with brown-yellow granules in the nucleus were defined as TUNEL-positive cells. Five fields were randomly chosen in each sample. The number of TUNEL-positive cells per field, under a 400- or 200-fold microscope, was counted and averaged with a BI-

---

**Table 9. Sequence of primers used in RT-qPCR.**

| Primer    | Primer sequence (5'-3') |
|-----------|-----------------------|
| GAPDH     | F: CTGACATGCGAGGGAGA  |
| U6        | F: ATGACGTCTGCGTGGAGAAC |
| Sirt1     | F: GTCATGCTCCTCCAGTTGCT |
| NF-κBp65  | F: GTGCGGAGAAAAACATGGGAGT |
| MiR-155   | F: GGAGTTAAGGCTATTGTAGT |
| BNDT      | F: CTGCTTCAAGGGCCCTTTCG |
| GAPDH     | R: ATGAGGGCCATGAGGTCAC |
| U6        | R: TCAGTGCTACGGAGTTCCAG |
| Sirt1     | R: CTGCGTGGTCCACATCGCGT |
| NF-κBp65  | R: AGGCTAGGGTCAAGGCATGG |
| MiR-155   | R: GTGCAGGGYCCAGG |
| BNDT      | R: TGCTGTGGGTATTGCGTCTGT |

Note: F, forward; R, reverse; GAPDH, glyceraldehyde phosphate dehydrogenase; miR-155, microRNA-155; BNDT, brain-derived neurotrophic factor.
HF cell model in primary rat cardiomyocytes from suckling rats

Ventricles from SD rats (2-3-day-old) were obtained and washed with Hank's solution (pH 7.2-7.4) 3 times. Tissues were cut into small pieces and detached with 0.25% trypsin at 37°C for 10 min. Trypsin solution was replaced by fresh 0.25% trypsin and incubated for another 30 min at 37°C. Tissues were washed with Hank's solution again for another 3 times. Cells that were fully dispersed were adjusted to 2 × 10⁶ cells/mL with Dulbecco's modified eagle medium (DMEM) containing 20% fetal bovine serum and were incubated for 4 hours at 37°C in a 5% CO₂ incubator. Adherent cells were discarded. The survival rate of floating cells was observed after trypan blue staining. When cell survival rate achieved > 95%, cells (100 μL/well) were transferred to a 96-well culture plate and cultured at 37°C with 5% CO₂ for 7 days. H₂O₂ (100 m/L in 10% serum culture medium) was added and incubated for 30 min to induce HF model in cardiomyocytes.

Transfection in primary rat cardiomyocytes

Cardiomyocytes treated with H₂O₂ were divided into 6 transfection groups: (1) model + inhibitor NC (miR-155 inhibitor negative sequence), (2) model + miR-155 inhibitor (miR-155 inhibitor plasmid), (3) model + mimic NC group (miR-155 mimic negative sequence), (4) model + miR-155 mimic (miR-155 mimic plasmid), (5) model + miR-155 mimic + oe-BDNF NC (miR-155 mimic plasmid + BDNF overexpression negative sequence), and (6) model + miR-155 mimic + oe-BDNF (miR-155 mimetic plasmid + BDNF overexpression plasmid). Cardiomyocytes were seeded in a six-well plate for 24 hours before transfection to allow the cell confluence to reach about 70%. Lipofectamine 2000 liposomes (20 μL, 11668019, Thermo Fisher Scientific, Waltham, MA, USA) were diluted in a 500 μL serum-free culture medium and incubated with cardiomyocytes for 5 min at room temperature. Plasmids and liposomes were mixed and incubated for 20 min at room temperature. The cardiomyocytes were washed three times with a serum-free culture medium. The medium was added, incubated with liposome mixture for 5-24 hours, and replaced every 6 hours during transfection. Cardiomyocytes were incubated with 20% antibiotic-free DMEM for 48 hours after being washed three times with serum-free medium. RT-qPCR was used to validate the interference efficiency of shRNA (sh-NF-κB p65#1, sh-NF-κB p65#2, sh-NF-κB p65#3). ShRNA that caused the lowest expression of NF-κB p65 was used for further experiments.

Chromatin immunoprecipitation (ChIP) assay

The enrichment of NF-κB p65 in the promoter region of miR-155 gene was determined by a ChIP kit (Millipore, Burlington, MA, USA). Cells in the logarithmic growth phase were mixed with 1% formaldehyde for 10 min at room temperature to allow DNA-protein cross-links to form. Cross-links formed were fragmented to an appropriate size by ultrasonic device for 10 seconds for 15 times with 10 second intervals after each cycle. Parts of the cross-link fragments were centrifuged at 13,000 rpm at 4°C, while the remaining fragments were used as ChIP Input. The supernatant was collected into three tubes and incubated with primary rabbit anti-rat NF-κB p65 (ab19870, Abcam, Cambridge, UK) or NC IgG antibodies overnight at 4°C. Endogenous DNA-protein complexes were precipitated by protein agarose/ sepharose. After centrifugation, supernatant was discarded. Cross-link proteins were allowed to break down at 65°C overnight. DNA fragments were then purified by phenol/chloroform extraction. The binding of NF-κB p65 to the promoter region of miR-155 (Table 9) was determined using Input as an internal reference.

Dual luciferase reporter gene assay

WT and MUT site sequences of the 3'-untranslated region (UTR) in BDNF mRNA were digested. Target gene fragments of WT and MUT were inserted into pmiR-RB-REPORT™ vectors (Guangzhou RiboBio Biotechnology Co., Ltd., Guangzhou, China) that had been digested previously with restriction endonucleases. The empty plasmid transfection served as a control. Vectors containing MUT and WT were co-transfected into HEK293T cells with NC mimics or miR-155 mimics, respectively. Cells were collected and lysed, centrifuged for 3-5 min, and allowed the supernatant to be collected after 48 hours of transfection. Relative light units (RLUs) were determined by Renilla Luciferase Assay Kit (YDJ2714, Yuduo Biotechnology Co., Ltd., Shanghai, China) using Firefly luciferase as an internal reference. Results between Renilla and Firefly luciferase were analyzed by using a dual luciferase reporter assay system (Promega Co., Madison, WI, USA).

3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) assay

Cardiomyocytes were detached with 0.25% trypsin to prepare single cell suspensions. Cells (0.2 mL) were inoculated at 3-6 × 10⁶ cells/well in 96-well plates (6 wells/group). Each of the culture mediums was replaced by a medium containing 10% MTT solution (5 g/L, GD-Y1317, Gudu Biotech Co., Ltd., Shanghai, China) and allowed to culture for 4 hours at 24-hour, 48-hour and
72-hour time intervals. The supernatant was removed and 100 μL of dimethyl sulfoxide (D5879-100ml, Sigma, St. Louis, MO, USA) was added and fully mixed for 10 min. Formazan crystals produced by living cells were detected by a microplate reader set at 570 nm (BS-1101, Detie Equipment Ltd., Nanjing, China).

Flow cytometry

Cells were detached with 0.25% trypsin (without ethylene diamine tetraacetic acid, EDTA), centrifuged and the supernatants discarded after transfection for 48 hours. Cells were washed 3 times with cold PBS, and centrifuged to discard the supernatant. TUNEL staining was based on Annexin-V-FITC Apoptosis Detection Kit (556547, Surej Biotechnology Co., Ltd., Shanghai, China). Staining solution was prepared by mixing Annexin-V-FITC, PI, HEPES buffer solution and Annexin-V/PI dye solution at 1:2:50 ratio. Cells at 1 × 10^6 cells/100 μL were left to stain for 15 min at room temperature and HEPES buffer solution (1 mL) was added and mixed homogeneously. Apoptotic cells were observed by flow cytometry (Bio-Rad ZE5, Hercules, CA, USA). The absorption and excitation wavelengths of FITC were 488 nm and 525 nm, respectively; the absorption and excitation wavelengths of PI-DNA were 535 nm and 615 nm, respectively.

Statistical analysis

Data were analyzed by SPSS version 21.0 (IBM, Chicago, IL, USA) and were expressed as a mean ± standard deviation. A comparison of data from 2 groups was performed by an unpaired t test, while 3 or more groups were analyzed by one-way analysis of variance (ANOVA) and Tukey's post hoc test. Data comparison between different time points was performed by repeated measures of ANOVA and Bonferroni post hoc test. Differences were considered statistically significant when p < 0.05.

Abbreviations

HF: Heart failure; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; miR: microRNA; BDNF: brain-derived neurotrophic factor; Sirt: Sirtuin; LVEF: left ventricular ejection fraction; NC: negative control; LVPWD: determine left ventricular posterior wall thickness; IVSD: interventricular septal dimension; LVEDD: left ventricular end diastolic diameter; LVESD : left ventricular end systolic diameter; FS: fractional shortening; LVSP: Left ventricular systolic pressure; LVEDP: left ventricular end diastolic pressure; HR: heart rate; HEPES: hydroxyethyl piperazine ethanesulfonic acid; RVM: right ventricular mass index; RVMI: right ventricular mass index; CVF: Collagen volume fraction; ChIP: Chromatin immunoprecipitation; WT: Wild-type; MUT: mutated; UTR: 3'-untranslated region; RLU: relative light units; ANOVA: analysis of variance.

AUTHOR CONTRIBUTIONS

B L, H Z, L L, ZZ Z, N J and XW Y. designed the study. B L, T Z, BW L, YK L and C Z collated the data, carried out data analyses and produced the initial draft of the manuscript. JX W, F W, DG F and J X contributed to drafting the manuscript. All authors have read and approved the final submitted manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

No funding was provided for this research.

Editorial note

*This corresponding author has a verified history of publications using a personal email address for correspondence.

REFERENCES

1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017; 3:7–11. https://doi.org/10.15420/cfr.2016:25:2 PMID: 28785469

2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, et al, Writing Committee Members, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128:e240–327. https://doi.org/10.1161/CIR.0b013e31829e8776 PMID:23741058

3. Roger VL. Epidemiology of heart failure. Circ Res. 2013; 113:646–59. https://doi.org/10.1161/CIRCRESAHA.113.300268 PMID:23989710

4. Zhang Y, Zhang J, Butler J, Yang X, Xie P, Guo D, Wei T, Yu J, Wu Z, Gao Y, Han X, Zhang X, Wen S, et al, and China-HF Investigators. Contemporary epidemiology,
management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry. J Card Fail. 2017; 23:868–75. https://doi.org/10.1016/j.cardfail.2017.09.014 PMID:29029965

5. Yu Y, Gupta A, Wu C, Masoudi FA, Du X, Zhang J, Krumholz HM, Li J, and China PEACE Collaborative Group. Characteristics, management, and outcomes of patients hospitalized for heart failure in China: the China PEACE retrospective heart failure study. J Am Heart Assoc. 2019; 8:e012884. https://doi.org/10.1161/JAHA.119.012884 PMID:31431117

6. Mele L, Maskell LJ, Stuckey DJ, Clark JE, Heads RJ, Budhram-Mahadeo VS. The POU4F2/8Rn-3b transcription factor is required for the hypertrophic response to angiotensin II in the heart. Cell Death Dis. 2019; 10:621. https://doi.org/10.1038/s41419-018-1848-y PMID:31413277

7. Tanno M, Kuno A, Horio Y, Miura T. Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol. 2012; 107:273. https://doi.org/10.1007/s00395-012-0273-5 PMID:22622703

8. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+ -dependent histone deacetylase SIRT1. J Biol Chem. 2007; 282:6823–32. https://doi.org/10.1074/jbc.M609554200 PMID:17197703

9. Sundaresan NR, Pillai VB, Gupta MP. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol. 2011; 51:614–18. https://doi.org/10.1016/j.yjmcc.2011.01.008 PMID:21276800

10. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K. SIRT1 longevity factor suppresses NF-kappaB -driven immune responses: regulation of aging via NF-kappaB acetylation? Bioessays. 2008; 30:939–42. https://doi.org/10.1002/bies.20799 PMID:18800364

11. Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, Kaarniranta K. Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci. 2008; 65:1049–58. https://doi.org/10.1007/s00018-008-7461-3 PMID:18193389

12. Dąbek J, Kulach A, Gąsior Z. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB): a new potential therapeutic target in atherosclerosis? Pharmacol Rep. 2010; 62:778–83. https://doi.org/10.1016/s1734-1140(10)70338-8 PMID:21098861

13. Gorski PA, Jang SP, Jeong D, Lee A, Lee P, Oh JG, Chepurko V, Yang DK, Kwak TH, Eom SH, Park ZY, Yoo YJ, Kim DH, et al. Role of SIRT1 in modulating acetylation of the sarco-endoplasmic reticulum Ca2+-ATPase in heart failure. Circ Res. 2019; 124:e63–80. https://doi.org/10.1161/CIRCRESAHA.118.313865 PMID:30786847

14. Han S, Li Z, Han F, Jia Y, Qi L, Wu G, Cai W, Xu Y, Li C, Zhang W, Hu D. ROR alpha protects against LPS-induced inflammation by down-regulating SIRT1/NF-kappa B pathway. Arch Biochem Biophys. 2019; 668:1–8. https://doi.org/10.1016/j.abb.2019.05.003 PMID:31071300

15. Yu H, Zhang F, Guan X. Baicalin reverse depressive-like behaviors through regulation SIRT1-NF-kB signaling pathway in olfactory bulbectomized rats. Phytother Res. 2019; 33:1480–89. https://doi.org/10.1002/ptr.6340 PMID:30848526

16. Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Müller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G. NF-kB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015; 29:535–47. https://doi.org/10.1038/leu.2014.231 PMID:25092144

17. Chen C, Luo F, Liu X, Lu L, Xu H, Yang Q, Xue J, Shi L, Li J, Zhang A, Liu Q. NF-kB-regulated exosomal miR-155 promotes the inflammation associated with arsenite carcinogenesis. Cancer Lett. 2017; 388:21–33. https://doi.org/10.1016/j.canlet.2016.11.027 PMID:27913196

18. Marques FZ, Vizi D, Khammy Q, Mariani JA, Kaye DM. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail. 2016; 18:1000–08. https://doi.org/10.1002/ejhf.517 PMID:27072074

19. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013; 128:1420–32. https://doi.org/10.1161/CIRCULATIONAHA.112.001357 PMID:23956210

20. Varendi K, Kumar A, Härma MA, Andressoo JO. miR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF. Cell Mol Life Sci. 2014; 71:4443–56. https://doi.org/10.1007/s00018-014-1628-x PMID:24804980
21. Varende K, Mátilik K, Andressoo JO. From microRNA target validation to therapy: lessons learned from studies on BDNF. Cell Mol Life Sci. 2015; 72:1779–94. https://doi.org/10.1007/s00018-015-1836-z PMID:25601223

22. Mackin P, Gallagher P. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol. 2005; 105:352. https://doi.org/10.1016/j.ijcard.2005.06.063 PMID:16087255

23. Matsumoto J, Takada S, Kinugawa S, Furihata T, Nambu H, Kakutani N, Tsuda M, Fukushima A, Yokota T, Tanaka S, Takahashi H, Watanabe M, Hatakeyama S, et al. Brain-derived neurotrophic factor improves trophic factor improves drion as a target for heart. Circulation. 2018; 138:2064–66. https://doi.org/10.1161/CIRCULATIONAHA.118.035212 PMID:30372141

24. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999; 100:999–1008. https://doi.org/10.1161/01.cir.100.9.999 PMID:10468532

25. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111:2837–49. https://doi.org/10.1161/CIRCULATIONAHA.104.500546 PMID:15927992

26. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013; 18:239–50. https://doi.org/10.1016/j.cmet.2013.07.002 PMID:23931755

27. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp. 2006; 274:3–12. https://doi.org/10.1002/0470029331.ch2 PMID:17019803

28. Hsu CP, Odewale I, Alcendor RR, Sadoshima J. Sirt1 protects the heart from aging and stress. Biol Chem. 2008; 389:221–31. https://doi.org/10.1515/BC.2008.032 PMID:18208353

29. Prola A, Pires Da Silva J, Guilbert A, Lecru L, Piquereau J, Ribeiro M, Mateo P, Gressette M, Fortin D, Boursier C, Gallerne C, Caillard A, Samuel J, et al. SIRT1 protects the heart from ER stress-induced cell death through elf2α deacetylation. Cell Death Differ. 2017; 24:343–56. https://doi.org/10.1038/cdd.2016.138 PMID:27911441

30. D’Onofrio N, Servillo L, Balestrieri ML. SIRT1 and SIRT6 signaling pathways in cardiovascular disease protection. Antioxid Redox Signal. 2018; 28:711–32. https://doi.org/10.1089/ars.2017.7178 PMID:28661724

31. Grillon JM, Johnson KR, Kotlo K, Danziger RS. Non-histone lysine acetylated proteins in heart failure. Biochim Biophys Acta. 2012; 1822:607–14. https://doi.org/10.1016/j.bbadis.2011.11.016 PMID:22155497

32. Papait R, Greco C, Kunderfranco P, Latronico MV, Condorelli G. Epigenetics: a new mechanism of regulation of heart failure? Basic Res Cardiol. 2013; 108:361. https://doi.org/10.1007/s00395-013-0361-1 PMID:23740219

33. Lee CF, Tian R. Mitochondrion as a target for heart failure therapy- role of protein lysine acetylation. Circ J. 2015; 79:1863–70. https://doi.org/10.1253/circj.CJ-15-0742 PMID:26248514

34. Fukushima A, Milner K, Gupta A, Lopaschuk GD. Myocardial energy substrate metabolism in heart failure : from pathways to therapeutic targets. Curr Pharm Des. 2015; 21:3654–64. https://doi.org/10.2174/1381612821666150710150445 PMID:26166604

35. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001; 107:7–11. https://doi.org/10.1172/JCI11830 PMID:11134171

36. Kieser A. Pursuing different ‘TRADDes’: TRADD signaling induced by TNF-receptor 1 and the epstein-barr virus oncoprotein LMP1. Biol Chem. 2008; 389:1261–71. https://doi.org/10.1515/BC.2008.144 PMID:18713013

37. Chen JG, Xu XM, Ji H, Sun B. Inhibiting miR-155 protects against myocardial ischemia/reperfusion injury via targeted regulation of HIF-1α in rats. Iran J Basic Med Sci. 2019; 22:1050–58. https://doi.org/10.22038/ijbms.2019.34853.8270 PMID:31807249

38. Hu J, Huang CX, Rao PP, Cao GQ, Zhang Y, Zhou JP, Zhu LY, Liu MX, Zhang GG. MicroRNA-155 inhibition attenuates endoplasmic reticulum stress-induced cardiomyocyte apoptosis following myocardial infarction via reducing macrophage inflammation. Eur J Pharmacol. 2019; 857:172449. https://doi.org/10.1016/j.ejphar.2019.172449 PMID:31207208

39. Takashio S, Sugiyama S, Yamamuro M, Takahama H, Hayashi T, Sugano Y, Izumiya Y, Hokimoto S, Minamino N, Yasuda S, Anzai T, Ogawa H. Significance of low
plasma levels of brain-derived neurotrophic factor in patients with heart failure. Am J Cardiol. 2015; 116:243–49.
https://doi.org/10.1016/j.amjcard.2015.04.018
PMID: 25983281

40. Feng N, Huke S, Zhu G, Tacchetti CG, Shi S, Aiba T, Kaludercic N, Hoover DB, Beck SE, Mankowski JL, Tomasselli GF, Bers DM, Paolocci N. Constitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation. Proc Natl Acad Sci USA. 2015; 112:1880–85.
https://doi.org/10.1073/pnas.1417949112
PMID: 25583515

41. Katare RG, Kakinuma Y, Arikawa M, Yamasaki F, Sato T. Chronic intermittent fasting improves the survival following large myocardial ischemia by activation of BDNF/VEGF/PI3K signaling pathway. J Mol Cell Cardiol. 2009; 46:405–12.
https://doi.org/10.1016/j.yjmcc.2008.10.027
PMID: 19059263

42. Liu Z, Tian H, Cai W, Bai Y, Zhan Q, Lai W, Zeng Q, Ren H, Xu D. A CRM1 inhibitor alleviates cardiac hypertrophy and increases the nuclear distribution of NT-4-PGC-1α in NRVMs. Front Pharmacol. 2019; 10:465.
https://doi.org/10.3389/fphar.2019.00465
PMID: 31133853

43. Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019; 18:45.
https://doi.org/10.1186/s12933-019-0849-6
PMID: 30935417

44. Mori D, Miyagawa S, Matsuura R, Sougawa N, Fukushima S, Ueno T, Toda K, Kuratani T, Tomita K, Maeda N, Shimomura I, Sawa Y. Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype. Cardiovasc Diabetol. 2019; 18:39.
https://doi.org/10.1186/s12933-019-0829-x
PMID: 30902059

45. Shimizu K, Kawakami S, Hayashi K, Kinoshita H, Kuwahara K, Nakao K, Hashida M, Konishi S. In vivo site-specific transfection of naked plasmid DNA and siRNAs in mice by using a tissue suction device. PLoS One. 2012; 7:e41319.
https://doi.org/10.1371/journal.pone.0041319
PMID: 22844458

46. Ma Y, Huang D, Yang F, Tian M, Wang Y, Shen D, Wang Q, Chen Q, Zhang L. Long noncoding RNA highly upregulated in liver cancer regulates the tumor necrosis factor-α-induced apoptosis in human vascular endothelial cells. DNA Cell Biol. 2016; 35:296–300.
https://doi.org/10.1089/dna.2015.3203
PMID: 26981838

47. Ayuk SM, Abrahamse H, Houreld NN. The role of photobiomodulation on gene expression of cell adhesion molecules in diabetic wounded fibroblasts in vitro. J Photochem Photobiol B. 2016; 161:368–74.
https://doi.org/10.1016/j.jphotobiol.2016.05.027
PMID: 27295416